Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02351167 · ClinicalTrials.gov registry record · Phase 4
Genetically Informed Smoking Cessation Trial
A Phase 4 study of Smoking Cessation, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 822
- Enrollment target
- 1
- Study location
NCT02351167: Completed Phase 4 study of Smoking Cessation, sponsored by Washington University School of Medicine.
NCT02351167 is a Phase 4 study of Smoking Cessation that has completed, run by Washington University School of Medicine. The registered enrollment target is 822 participants, above the 470-participant average among 188 other Smoking Cessation trials with a reported enrollment target (75% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02351167, a Phase 4 study of Smoking Cessation, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 822 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators' goal is to identify the most appropriate smoking cessation treatments for smokers based on genetic information. Smokers try to quit smoking but relapses are common.
Primary Outcome
The definition of this measure requires: (a) no self-reported smoking (not even a puff of a cigarette) for at least the 7 days prior to the assessment, and (b) biochemical verification of abstinence.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Varenicline
- DRUG Combination NRT (Nicotine patch, Nicotine lozenge)
- BEHAVIORAL Intensive smoking counseling
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 822 participants |
| Start Date | 2015-05-20 |
| Est. Completion | 2019-08-31 |
| Phase | Phase 4 |
What the finished NCT02351167 record still lists
NCT02351167 is an interventional study that assigns participants to a tested intervention. The registered 822 participants enrollment target is mid-sized for trials with a published cap, above the 470-participant average among 188 other Smoking Cessation trials with a reported enrollment target (75% higher).
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02351167 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT02351167 about?
NCT02351167 is a clinical study titled "Genetically Informed Smoking Cessation Trial". The investigators' goal is to identify the most appropriate smoking cessation treatments for smokers based on genetic information. Smokers try to quit smoking but relapses are common.
What is the current status of trial NCT02351167?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 822 participants. The study started on 2015-05-20. Estimated completion is 2019-08-31.
What conditions does trial NCT02351167 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT02351167?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG), Combination NRT (Nicotine patch, Nicotine lozenge) (DRUG), Intensive smoking counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT02351167?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02351167 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02351167's enrollment target sits among peer trials
822 29th of 188 higher than 160 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
RECRUITING · Phase 4
-
The Options 2 Study
RECRUITING · Phase 4
-
Smoking Cessation Program in the Construction Sector
RECRUITING · Phase 4
-
The Avenues Study: Dual Use Cessation
RECRUITING · Phase 4
-
Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care
RECRUITING · Phase 4
-
Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05679349 · 822 participants · NA
Support and Outreach to Increase Screening for Lung Cancer in Patients With a History of Smoking
- NCT06091254 · 822 participants · Phase 3
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- NCT07357389 · 822 participants · NA
Virtual Reality for ICU Delirium Prevention
- NCT06944509 · 824 participants · NA
RADIQAL Study (Radiation Dose and Image Quality Trial)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI